Parkinson's gut bacteria and L-dopa response study
Part of Brain & nervous system clinical trials.
This study explores how bacteria in the small intestine affect how well the Parkinson's medication L-dopa works. It involves swallowing a special capsule to collect gut samples.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 to 85 years old
- Diagnosed with Parkinson's disease and have had a good response to L-dopa
- Take an immediate-release form of L-dopa at a stable dose for at least 2 months
- Able to swallow a large capsule (about 1 inch long) while in the OFF state
- No history of dementia, swallowing problems, or recent antibiotic use
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how diet and the bacteria in your gut (microbiome) affect Parkinson's symptoms. You'll work with a coach and take cooking classes to see if changing what you eat can help you feel better.
This study looks at how digestive (gut) problems happen in people with Parkinson’s and whether there are related changes in the nerve tissue in the digestive tract. It may help researchers better understand the cause of these symptoms and find new ways to monitor or treat them.
This study looks at how certain gut bacteria (methanogens) are involved in the progression of Parkinson's disease and related conditions. It aims to understand the connection between gut health and brain health, which may lead to better treatments.
This study is looking at how the bacteria in your gut might affect your brain in Parkinson's disease. It involves two types of brain scans to see differences between people with Parkinson's and healthy volunteers.
This trial studies nerve cell “biomarkers” from the gut to learn whether they can help detect Parkinson’s disease (or related conditions) earlier. You may be asked to undergo a colonoscopy to collect gut tissue for testing.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.